Search

The aim of the present study was to investigate the antibiotic resistance and bio lm formation among a collection of 51 clinical isolates of Staphylococcus pseudintermedius collected from canine pyoderma. All isolates were tested for the susceptibility to a panel of 14 antimicrobial agents by the disk di usion method in Müeller-Hinton agar. Oxacillin resistance was detected by subculture on oxacillin screening agar base. Bio lm formation was investigated by the Microtitre Plate test (MtP) and for some strains by transmission electron microscopy (TEM). Antibiotic resistance pro ling demonstrated that 45/51 S. pseudintermedius isolates had a multi drug resistant (MDR) phenotype, exhibiting simultaneous resistance to at least 3 antibiotics categories; whereas 6 isolates showed a non-MDR phenotype. Thirty strains (59%) were resistant in oxacillin resistant screening agar, the same strains were also positive for mecA by PCR assay. All S. pseudintermedius isolates showed bio lm production by MtP method. Seventeen out of 51 isolates were classi ed as weakly adherent, 26 as moderately adherent, and 8 as strongly adherent. Moreover, no di erence in bio lm formation between meticillin-resistant S. pseudintermedius (MRSP) and meticillin-suscebtible S. pseudintermedius (MSSP) (P value0.05) was noted. The antimicrobial resistance mechanisms and bio lm formation could explain the di culty in treating S. pseudintermedius canine infections, chemotherapeutic failure, and consequently persistent infections.

Inflammatory bowel diseases (IBD) are characterized by inflammatory conditions of the intestine. Probiotic bacteria (PB) can have beneficial effects in several gastrointestinal disorders. The objectives of this study were: (i) to provide an acute experimental IBD model induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS) in CD-1 mice, and (ii) to assess the preventive effects of Citogenex (Lactobacillus casei and Bifidobacterum lactis) supplementation on intestinal tissues and microbiota. Mice were inoculated intrarectally with saline, ethanol or different TNBS solutions. 1%TNBS induced clinical signs of colitis (P less than 0.01) and histological damage (P less than 0.01). Based on these results, mice were pre-treated with Citogenex or saline for 1, 2 or 3 weeks before 1%TNBS treatment. Probiotic pre-treatment determined a reduction of clinical signs (P less than 0.05), histological alterations of colitis (P less than 0.05) and increased beneficial bacteria (P less than 0.05). This study confirms that TNBS-induced colitis in CD-1 mice is useful for studying the mechanisms involved in IBD pathogenesis, and pre-treatment with Citogenex prevents the intestinal damage induced by TNBS.

This paper reviews the composition of colostrum and the potential preventive and therapeutic use of this "first milk" for treating various gastrointestinal disorders in humans. Colostrum is a complex biological liquid that is richer in antimicrobial peptides, immune-regulating compounds and growth factors than the subsequent mature milk. The main functions of colostrum are to provide essential nutritional components, strengthen the natural defense system, modulate immune response, balance intestinal microbiota and enhance the growth and repair of several tissues. Several studies and clinical trials carried out both in vitro and in vivo on humans and animals suggest the clinical benefits of bovine colostrum (BC) supplementation in gastro-intestinal diseases. Despite the encouraging results, further well-designed studies are required in order to confirm these effects, the dose and duration of treatment. Colostrum is safe since there are no contraindications regarding high dose levels and few side effects of clinical relevance have been reported. In conclusion, in the near future, colostrum-based supplements may play a complementary role to synthetic drugs in the prevention and treatment of various gastrointestinal disorders.